Chang Ling-Sai, Yu Hong-Ren, Chu Chiao-Lun, Chen Kuang-Den, Huang Ying-Hsien, Guo Mindy Ming-Huey, Weng Ken-Pen, Kuo Ho-Chang
Department of Pediatrics and Kawasaki Disease Center, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung 83301, Taiwan.
Institute for Translational Research in Biomedicine, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung 83301, Taiwan.
J Clin Med. 2021 May 27;10(11):2347. doi: 10.3390/jcm10112347.
The Fc gamma receptor family contains several activating receptors and the only inhibitory receptor, . In this study, we investigated the dynamic methylation change of in different stages of Kawasaki disease (KD). We enrolled a total of 116 participants, which included patients with febrile diseases as controls and KD patients. Whole blood cells of KD patients were collected prior to intravenous immunoglobulin (IVIG) treatment (KD1), three to seven days after IVIG (KD2), three weeks after IVIG treatment (KD3), six months after IVIG (KD4), and one year after IVIG treatment (KD5). In total, 76 KD patients provided samples in every stage. Leukocytes of controls were also recruited. We performed DNA extraction and pyrosequencing. methylation levels were higher in KD3 compared to both the controls and KD1. A significantly higher methylation of was found in KD5 when compared with KD1. methylation levels in the IVIG-resistant group were lower than those in the IVIG-responsive group at KD1-3 ( = 0.004, 0.004, 0.005 respectively). This study is the first to report the dynamic change of methylation and to demonstrate long-term hypermethylation one year after disease onset. Hypomethylation of is associated with IVIG resistance.
Fcγ受体家族包含多个激活受体和唯一的抑制性受体。在本研究中,我们调查了川崎病(KD)不同阶段该受体的动态甲基化变化。我们共招募了116名参与者,其中包括作为对照的发热性疾病患者和KD患者。KD患者的全血细胞在静脉注射免疫球蛋白(IVIG)治疗前(KD1)、IVIG治疗后三至七天(KD2)、IVIG治疗后三周(KD3)、IVIG治疗后六个月(KD4)以及IVIG治疗后一年(KD5)采集。总共76名KD患者在每个阶段都提供了样本。同时也招募了对照的白细胞。我们进行了DNA提取和焦磷酸测序。与对照组和KD1相比,KD3中该受体的甲基化水平更高。与KD1相比,KD5中该受体的甲基化显著更高。在KD1 - 3阶段,IVIG抵抗组中该受体的甲基化水平低于IVIG反应组(分别为P = 0.004、0.004、0.005)。本研究首次报道了该受体甲基化的动态变化,并证明疾病发作一年后存在长期高甲基化。该受体的低甲基化与IVIG抵抗相关。